Quo Vadis, Cochrane Collaboration? by Jokstad, Asbjørn
DOI: 10.1002/cre2.176E D I TO R I A LQuo Vadis, Cochrane Collaboration?The Cochrane Collaboration became a registered British charity in
1995; hence a few years after the first Cochrane centre opened in
November 1992 in U.K. (U.K. Charity Commission, 2019a). Public
information reveals that the charity maintains a staff of 64 employees
and that the annual income and endowments to the central organiza-
tion in 2017 total 8.7 million GBP and it retains assets over 7 million
GBP (U.K. Charity Commission, 2019b). The significant bulk of the
income is publication royalties from John Wiley and sons. A further
15.6 million GBP funded a global network of more than 38 thousand
collaborators in 120 countries received from national governments,
international governmental and non‐governmental organizations,
universities, hospitals, private foundations, and personal donations
(https://www.cochrane.org/about‐us/our‐funders‐and‐partners). It is
perplexing and sad to read that this once idealistic organization is
currently undergoing a crisis and tormented by multiple escalating
controversies (Newman, 2019).
Upon scrutiny of recent articles, letters and multiple blogs, the
issues that are being raised are about centralization, corporatization,
governance and perceived conflicts of interest. Several allegations have
been claimed of a near‐Orwellian‐like organizational culture introduced
in 2015 to bolster the new brand “Cochrane” (http://fabrikbrands.com/
portfolio/cochrane‐branding). The central office of the charity man-
dated all to stop referring to the full name of the charity, i.e., Cochrane
Collaboration, with the notion that by only referring to “Cochrane” “..
make things clear and consistent and maximize impact” (Cochrane
brand, 2019a). The latest brand guidelines is a 144‐page document that
details what to do and say and what not, and with suggestions on how
to describe the charity, its history and its current efforts and visions
with many beautiful words (Cochrane brand, 2019b).
It seems to undersigned that this initially idealistic charity has
contracted some form of Icarus syndrome prompted by seduction to
generate substantial revenues rather than strengthening the actual
value of the offered products, i.e., the access to the databases of RCTs
and systematic reviews (SR) and quality assurance of the latter cate-
gory. Moreover, from a research ethics perspective, one may question
why the Cochrane Collaboration has still not established a policy not
to include in SRs primary studies that fail to report an approval by
an ethics committee or institutional review board (Jokstad, 2017).
The charity has repeatedly stated that one of the main goals is to
make evidence accessible and useful to everybody, everywhere in the- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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open access (OA) which is: “ … maintaining and expanding Cochrane
Library revenues” (Cochrane, 2019). The initiative for OA launched
by Science Europe in September 2018 seems not to be on the agenda
within the Cochrane Collaboration, as judged by a search on their
website. (Alternatively, the website search index has not been re‐
indexed lately). True, since 2013 a hybrid (“green”) access policy has
been in place, i.e., a 12 months embargo followed by open access,
alternatively an option for the authors of SRs to pay an article‐
processing charge (APC) of $5000 for full (“gold”) access (Cochrane
Open Access, 2019). This arrangement does not set the charity apart
and is analogue to the practices of most commercial publishers.
Moreover, the APC is higher than the APC of most commercial
publishers. The multiple “news” infrequently on Cochrane.org/news
about this and that country now having free access to Cochrane
SRs, usually complemented by the number of millions inhabiting the
specified country, is not because of the charity, but rather
because the contracted publisher of the Cochrane SRs, John Wiley &
Sons, endorse the Hinari initiative established by WHO in 2001
(WHO, 2019).
The “value” of the Cochrane SRs is a reputation of comprehen-
siveness and objectivity, which encompasses a thorough search for
trials and an impartial assessment of the identified evidence that
include estimations of the likelihood of bias. They may perhaps be
trustworthy, but they are not truths. Rather, they are best guesses,
sometimes including a range of uncertainty. When it comes to the like-
lihood of being false, a meta‐analysis of small, inconclusive studies is
statistically likely to have a positive predictive value (PPV, or false pos-
itive finding) that is below 50% under most premises (Ioannidis, 2005).
Stated another way, the great majority of Cochrane SRs currently fall
within this category, and the findings are therefore more likely to be
false than not false. The forest plot logo of the charity itself is a good
example of how one may become lured. The logo reflects a touching
narrative about baby lives that could have been saved if gynecologists
in the eighties had been aware of a handful of RCTs published starting
from the early seventies (Figure 1). Since many have accepted this
“truth”, WHO and NGOs committed to improving international social
inequalities made several initiatives to encourage the use of prenatal
corticosteroids for reducing morbidity and mortality after preterm
birth. However, a paper in Lancet appeared in 2014 titled “Extreme
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FIGURE 1 The old and the rebranded logo
of the Cochrane Collaboration (since Jan 30,
2015). The graph is designed to illustrate the
human costs that can result from failure to
prepare systematic, up‐to‐date reviews of
controlled trials of health care, such as the
effects of prenatal corticosteroids on the
likelihood of early neonatal mortality. Recent
research may demand a bottom text:
"Disclaimer: the findings shown in this logo
pertain only to certain regions and patient
populations."
4 EDITORIALcaution is needed before scale‐up of antenatal corticosteroids to
reduce preterm deaths in low‐income settings” (Azad & Costello,
2014), which seriously jolted the confidence of doing more good than
harm. WHO convened very rapidly an expert group, which concluded
that the generalisability of the available evidence demonstrate that a
true state of clinical equipoise exists for this treatment option in
low‐resource settings and that there was a clear need for more effi-
cacy trials of ACS in these settings (Vogel et al., 2017). Also, the latest
Cochrane SR on this topic added in the conclusions that “...the results
may not be applicable to low‐resource settings with high rates of
infections” (Roberts, Brown, Medley, & Dalziel, 2017). This message
is quite different from the earlier conclusions like “No adverse conse-
quences of prophylactic corticosteroids for preterm birth have been
identified” in the 2000 update, and “A single course of antenatal
corticosteroids should be considered routine for preterm delivery with
few exceptions” concluded in the 2006 update. One pertinent remark
is from the recognized founder of the charity, i.e., Iain Chalmers, who
blogged: Should the Cochrane logo be accompanied by a health warn-
ing? (Chalmers, 2016). An alternative way of reorienting or educating
readers would be to add the text below the logo stating: “Disclaimer:
the findings shown in this logo pertain only to certain regions and
patient populations”.
Upon reading the background history about the first SR on use of
prenatal corticosteroids (www.histmodbiomed.org/sites/default/files/
44848.pdf), one cannot help speculating whether the antagonists on
the safety of corticosteroids at the time were “biased” because they
had worked mostly within socially deprived communities or only with
healthier patients within more robust health care systems. Regardless,
between the two opposite beliefs of what was “trustworthy” at the
time, one continued to prevail (Crowley, 1981), forming also the basis
of the Cochrane Collaboration logo, while the other data and their
interpretations were relegated to obscurity (Sachs, 1981) – in retro-
spect perhaps unjustly based on the recent clinical findings. In sum,
it is not possible to generate numbers of a likelihood of “trustworthi-
ness” of data or meta‐data, even if the numbers are created by
prestigious investigators or by a consensus voting in an organization
or by an editorial team.Admittedly, it seems very logical that by conducting a meta‐
analysis on a set of RCTs judged to be “true”, one may derive an
estimate of effectiveness we believe is “trustworthy”, given that a
choice of potential biases has been identified and considered.
Unfortunately, this idea is not so simple from a statistical perspective
for at least two reasons.
The first reason is that effect estimations in most meta‐analyses
leave out the element of random errors between the studies, e.g., as
a reflection of small sample size and methodological heterogeneity
combined with multiple testing. One may approximate that seemingly
conclusive meta‐analyses become inconclusive (Brok, Thorlund,
Wetterslev, & Gluud, 2009) after applying statistical methods termed
recursive cumulative meta‐analysis (Ioannidis, Contopoulos‐Ioannidis,
& Lau, 1999) or trial sequential analyses (TSA) (Wetterslev, Thorlund,
Brok, & Gluud, 2008). Only a distinct minority of Cochrane SRs include
TSA‐analyses. Hence, “trusted evidence” may not be so trustworthy
after all, even if it comes from the Cochrane Collaboration, which
emphasizes once again that in science, one may never prove anything,
but rather one can disprove theories with a precise (low) level of
probability.
Secondly, the practice of appraising only “quality‐trials” and strat-
ifying meta‐analyses according to perceived bias has been criticized
for at least two decades. Already in 1999, a group of authoritative epi-
demiologists used regression models to examine whether the type of
quality assessment scale being used affected the conclusions of
meta‐analytic studies. Their advice from their findings was “..that the
use of summary scores to identify trials of high quality is problematic”
(Jüni, Witschi, Bloch, & Egger, 1999). Twenty years later, another
group of authoritative epidemiologists question why this practice is
still maintained in Cochrane SRs since “stratification by quality leads
to a form of selection bias, i.e., collider‐stratification bias, and should
be avoided” in favor of other approaches (Stone et al., 2019).
A critical take‐home message is that some SRs present only amal-
gamated facts, while others also give their interpretations of the facts.
These interpretations are invariably primed by their authors' theories,
values, and ideologies (Wieringa, Engebretsen, Heggen, & Greenhalgh,
2018). It takes a trained mindset to perceive the almost imperceptible
EDITORIAL 5border between these two types of SRs. Proponents of compiling SRs
that fit the first category can argue that non‐content experts can write
adequate SRs and that even in some circumstances, avoiding content
experts as co‐authors can be an advantage (Gøtzsche & Ioannidis,
2012). Proponents of complementing effectiveness with particular
dimensions such as harm, or equity, or health economy elements will
tend to both present and interpret the facts relative to these elements,
which introduces a risk of introducing authors' biases. Notoriously
controversial, are claims of the underreporting of side effects and risks
of harm associated with interventions.
SRs that follow the existing minimum requirements for publishing
results befitting the study design (https://www.equator‐network.org/)
has helped tremendously for more efficient reporting and reading. I
surmise that an SR reported according to the PRISMA format (Moher,
Liberati, Tetzlaff, Altman, & The PRISMA Group, 2009) should be
comparable with any Cochrane SR upon evaluation using AMSTAR
(A MeaSurement Tool to Assess systematic Reviews) (Shea et al.,
2007). Unfortunately, all SRs have shortcomings by default, including
both PRISMA‐format and Cochrane SRs. The reason is that they are
based only on what has been synthesized and published, and not on
all data that have been recorded in a clinical study. I.e., there are
always risks of potential outcome reporting biases in primary studies.
Multiple articles identify incongruences between study intentions
described in pretrial repositories and outcomes presented in final
publications. Hence, there is a growing recognition that the current
lack of open access to clinical study reports, and especially those
involving effects of drug interventions, remain a barrier to provide
unbiased evaluations. (Hodkinson et al., 2018). Perhaps the Cochrane
Collaboration may re‐establish a reputation of impartiality and fairness
by championing open access to clinical study reports as a basis for
Cochrane SRs.
Regardless, a strategy that gives an impression of the charity
becoming some sort of a moneymaking enterprise that rival “compet-
itors” should be abandoned. It is astonishing that a statement on
www: “Anyone who produces, or who finds a way to make systematic
reviews more digestible and more relevant to the audience, is in
competition with Cochrane” is attributed to the CEO of the charity.
In contrast, my persuasion is that most health care providers and
patients would like the charity to work together with and not compete
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